Redcare Pharmacy Defies Market Pessimism with Robust Quarterly Performance

Despite facing significant headwinds in its stock performance this year, Redcare Pharmacy has delivered a powerful demonstration of its underlying operational strength in the third quarter. The online pharmacy’s latest financial report reveals a company experiencing explosive growth in its core prescription business, even as its share price languishes near annual lows.

Financial Health Strengthens Amid Stock Decline

While Redcare’s equity value has declined by more than 45% since the beginning of the year and currently trades close to its 52-week low, the company’s financial metrics tell a different story. Total quarterly revenue advanced by 25% to reach €719 million. The company maintained solid profitability, with adjusted EBITDA coming in at €17.1 million, representing a 2.4% margin. This performance firmly places Redcare within its target corridor of 2.0% to 2.5%.

The balance sheet showed notable improvement, with cash reserves swelling to €266 million. The international division demonstrated marked progress, improving its EBITDA margin from -2.9% to -0.4%. Operational capacity received a significant boost with the recent opening of a new distribution facility in Pilsen, which adds handling capability for 15 million annual orders.

Prescription Business Accelerates Dramatically

The German prescription segment has emerged as the primary growth engine for Redcare, with performance exceeding expectations. Year-over-year growth accelerated dramatically to 82%, pushing prescription revenue to €126 million in the third quarter. Sequential growth also impressed, with the Rx business expanding by €12 million compared to the previous quarter—double the growth rate achieved in the second quarter.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

This robust expansion underscores the company’s successful penetration of the digital prescription market. Redcare is approaching the 1% threshold in the overall German prescription market and has already captured 1.2% of the total electronic prescription volume. This growing market share validates the company’s strategic focus on digital transformation within the prescription sector, though the increasing proportion of lower-margin prescription sales continues to pressure overall profitability margins.

Forward Guidance and Long-Term Prospects

Management reaffirmed its full-year 2025 outlook, maintaining expectations for:
– Revenue growth exceeding 25%
– German prescription sales surpassing €500 million
– Non-prescription revenue growth above 18%
– EBITDA margin between 2.0% and 2.5%

The company’s medium to long-term target margin of over 8% indicates substantial potential for profit expansion. The critical question facing investors is whether these strong operational results can ultimately reverse the persistent downward trend in the company’s share price.